Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
AlzeCure gets presentation accepted on disease-modifying effects of ACD856 at Alzheimer’s conference
September 26, 2023
-
AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference
September 20, 2023
-
AlzeCure gets an abstract on phase II clinical data with ACD440 for neuropathic pain accepted at pain conference
September 18, 2023